Cargando…

In Vitro Evaluation of Recombinant Bone Morphogenetic Protein-2 Bioactivity for Regenerative Medicine

Recombinant human bone morphogenetic protein-2 (rhBMP-2) is a commonly used growth factor in bone regeneration due to its high potency and ability to induce osteogenic differentiation of osteoblasts and osteoblast precursors. When designing delivery systems for rhBMP-2, the activity of the loaded an...

Descripción completa

Detalles Bibliográficos
Autores principales: Fung, Stephanie L., Wu, Xiaohuan, Maceren, Julian P., Mao, Yong, Kohn, Joachim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761583/
https://www.ncbi.nlm.nih.gov/pubmed/31418333
http://dx.doi.org/10.1089/ten.tec.2019.0156
_version_ 1783454052989796352
author Fung, Stephanie L.
Wu, Xiaohuan
Maceren, Julian P.
Mao, Yong
Kohn, Joachim
author_facet Fung, Stephanie L.
Wu, Xiaohuan
Maceren, Julian P.
Mao, Yong
Kohn, Joachim
author_sort Fung, Stephanie L.
collection PubMed
description Recombinant human bone morphogenetic protein-2 (rhBMP-2) is a commonly used growth factor in bone regeneration due to its high potency and ability to induce osteogenic differentiation of osteoblasts and osteoblast precursors. When designing delivery systems for rhBMP-2, the activity of the loaded and released protein is an important consideration. The variability in the experimental design parameters used to measure rhBMP-2 activity in vitro has precluded comparative analysis. Here, for the first time, we report a direct comparison of the assay parameters used in rhBMP-2 bioactivity assays in the literature and an evaluation of commercially available rhBMP-2 obtained from different vendors. Most published rhBMP-2 assays use W-20-17 (mouse stromal), MC3T3 (preosteoblast), or C2C12 (myoblast) cell lines. We found that each model cell line has an optimal concentration range over which it is most sensitive to rhBMP-2 induction. Therefore, it is difficult to find one single bioassay protocol that could be universally used. In addition, we established a correlation between protein concentration (as measured by enzyme-linked immunosorbent assay) and protein activity (as measured by alkaline phosphatase induction). We found that the expression system used to produce the rhBMP-2 had the greatest effect on its activity and stability in vitro. Establishing a standard method of measuring rhBMP-2 activity in vitro is the first step toward developing an in vitro–in vivo correlation between measured activity and clinical outcomes. IMPACT STATEMENT: This work is a systematic evaluation of the experimental parameters of the most widely used in vitro recombinant human bone morphogenetic protein-2 (rhBMP-2) activity assays. The variations in assays reported in the literature have challenged the reproducibility and translation of work using rhBMP-2 as a bone-inducing growth factor. By elucidating the effect of model cell line on the dose-dependent alkaline phosphatase response to rhBMP-2 induction and by establishing a correlation between protein activity and protein concentration by enzyme-linked immunosorbent assay using commercially available rhBMP-2, this work is a significant step toward developing an in vitro–in vivo correlation between quantified activity and clinical efficacy.
format Online
Article
Text
id pubmed-6761583
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Mary Ann Liebert, Inc., publishers
record_format MEDLINE/PubMed
spelling pubmed-67615832019-09-26 In Vitro Evaluation of Recombinant Bone Morphogenetic Protein-2 Bioactivity for Regenerative Medicine Fung, Stephanie L. Wu, Xiaohuan Maceren, Julian P. Mao, Yong Kohn, Joachim Tissue Eng Part C Methods Methods Articles Recombinant human bone morphogenetic protein-2 (rhBMP-2) is a commonly used growth factor in bone regeneration due to its high potency and ability to induce osteogenic differentiation of osteoblasts and osteoblast precursors. When designing delivery systems for rhBMP-2, the activity of the loaded and released protein is an important consideration. The variability in the experimental design parameters used to measure rhBMP-2 activity in vitro has precluded comparative analysis. Here, for the first time, we report a direct comparison of the assay parameters used in rhBMP-2 bioactivity assays in the literature and an evaluation of commercially available rhBMP-2 obtained from different vendors. Most published rhBMP-2 assays use W-20-17 (mouse stromal), MC3T3 (preosteoblast), or C2C12 (myoblast) cell lines. We found that each model cell line has an optimal concentration range over which it is most sensitive to rhBMP-2 induction. Therefore, it is difficult to find one single bioassay protocol that could be universally used. In addition, we established a correlation between protein concentration (as measured by enzyme-linked immunosorbent assay) and protein activity (as measured by alkaline phosphatase induction). We found that the expression system used to produce the rhBMP-2 had the greatest effect on its activity and stability in vitro. Establishing a standard method of measuring rhBMP-2 activity in vitro is the first step toward developing an in vitro–in vivo correlation between measured activity and clinical outcomes. IMPACT STATEMENT: This work is a systematic evaluation of the experimental parameters of the most widely used in vitro recombinant human bone morphogenetic protein-2 (rhBMP-2) activity assays. The variations in assays reported in the literature have challenged the reproducibility and translation of work using rhBMP-2 as a bone-inducing growth factor. By elucidating the effect of model cell line on the dose-dependent alkaline phosphatase response to rhBMP-2 induction and by establishing a correlation between protein activity and protein concentration by enzyme-linked immunosorbent assay using commercially available rhBMP-2, this work is a significant step toward developing an in vitro–in vivo correlation between quantified activity and clinical efficacy. Mary Ann Liebert, Inc., publishers 2019-09-01 2019-09-17 /pmc/articles/PMC6761583/ /pubmed/31418333 http://dx.doi.org/10.1089/ten.tec.2019.0156 Text en © Stephanie L. Fung et al., 2019; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Methods Articles
Fung, Stephanie L.
Wu, Xiaohuan
Maceren, Julian P.
Mao, Yong
Kohn, Joachim
In Vitro Evaluation of Recombinant Bone Morphogenetic Protein-2 Bioactivity for Regenerative Medicine
title In Vitro Evaluation of Recombinant Bone Morphogenetic Protein-2 Bioactivity for Regenerative Medicine
title_full In Vitro Evaluation of Recombinant Bone Morphogenetic Protein-2 Bioactivity for Regenerative Medicine
title_fullStr In Vitro Evaluation of Recombinant Bone Morphogenetic Protein-2 Bioactivity for Regenerative Medicine
title_full_unstemmed In Vitro Evaluation of Recombinant Bone Morphogenetic Protein-2 Bioactivity for Regenerative Medicine
title_short In Vitro Evaluation of Recombinant Bone Morphogenetic Protein-2 Bioactivity for Regenerative Medicine
title_sort in vitro evaluation of recombinant bone morphogenetic protein-2 bioactivity for regenerative medicine
topic Methods Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761583/
https://www.ncbi.nlm.nih.gov/pubmed/31418333
http://dx.doi.org/10.1089/ten.tec.2019.0156
work_keys_str_mv AT fungstephaniel invitroevaluationofrecombinantbonemorphogeneticprotein2bioactivityforregenerativemedicine
AT wuxiaohuan invitroevaluationofrecombinantbonemorphogeneticprotein2bioactivityforregenerativemedicine
AT macerenjulianp invitroevaluationofrecombinantbonemorphogeneticprotein2bioactivityforregenerativemedicine
AT maoyong invitroevaluationofrecombinantbonemorphogeneticprotein2bioactivityforregenerativemedicine
AT kohnjoachim invitroevaluationofrecombinantbonemorphogeneticprotein2bioactivityforregenerativemedicine